Non‐Glucocorticoid Immunosuppressive Therapy in Post‐Glucocorticoid Persistent or Recurrent Primary Autoimmune Hypophysitis: A Systematic Review
Authors' conclusion
NGITs are effective treatment modalities for post-GC therapy persistent or recurrent PAH.
Study context
- Population
- Post-GC persistent or recurrent primary autoimmune hypophysitis (PAH) managed with NGIT; recurrent after initial GC response 62.1%, persistent 37.9%incl
- Participants
- 29 participants
- Comparison
- Non-GC immunosuppressive therapy in post-GC persistent or recurrent PAH
- Multiple NGITsn = seven
- Outcome
- Effectiveness and safety of NGIT
Methodological detailsincludes two patients from authors' centre
- Includes two patients from authors' centre
Pooled result
As reported in the abstract
PAH remission with NGIT (overall)
Clinical remission
≈91%
Hormonal remission
≈26%
Radiological remission
≈72%
Further pooled results
| Outcome | RTX | MMF | AZA |
|---|---|---|---|
| Radiological response by agent | 100% | ≈66% | ≈37% |
Treatment characteristics
- Single NGIT agent
- 75.8%
- NGIT concomitant with GC
- 59.1%
- Duration of NGIT use, median (IQR)
- 10.5 (4.0-24.2) months
Safety
- Overall adverse events (mycophenolate mofetil (MMF): alopecia, hepatitis; Infliximab (IFX): pulmonary aspergillosis; AZA: hepatitis, leucopenia)
- ≈20%
Original publication
Non‐Glucocorticoid Immunosuppressive Therapy in Post‐Glucocorticoid Persistent or Recurrent Primary Autoimmune Hypophysitis: A Systematic Review. Clin Endocrinol (Oxf). Published 14 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →